Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | C1R | P00736 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30415489 | 1.00 | POLB (0.50) | POLBNR4A2ACHEBCHECHRM1 | |
| SCHEMBL3972257 | 0.83 | HRH3 (0.46) | POLBNR4A2ACHEBCHECHRM1 | |
| SCHEMBL29799170 | 0.83 | LMNA (0.46) | NR4A2ACHEBCHEESR1ESR2 | |
| SCHEMBL2535170 | 0.83 | LMNA (0.46) | NR4A2ACHEBCHEESR1ESR2 | |
| SCHEMBL23202854 | 0.79 | ACHE (0.42) | ACHEBCHEMPOKMT2A | |
| SCHEMBL1599226 | 0.79 | APP (0.38) | POLBNR4A2ESR1ESR2HRH3 | |
| SCHEMBL5640307 | 0.79 | NR4A2 (0.53) | POLBNR4A2ACHEBCHECHRM1 | |
| SCHEMBL7695488 | 0.79 | LMNA (0.52) | POLBACHEBCHEKMT2AC1R | |
| SCHEMBL32474876 | 0.79 | LMNA (0.52) | POLBACHEBCHEKMT2AC1R | |
| SCHEMBL4745343 | 0.79 | POLB (0.72) | POLBNR4A2ACHEBCHECHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735407-B1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | INST NAT SANTE RECH MED (FR) | 2026-04-01 | — | — | EP | disclosed |
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| EP-4486734-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-12091387-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
| US-6320051-B1 | AMINO(NH) OR OXYGEN(O) SUBSTITUTED, ENZYME INHIBITORS OF STAPHLOCCOCUS AUREUS METHIONYL T-RNA SYNTHETASE (MRS); ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2001-11-20 | — | — | US | disclosed |
| EP-1084110-A1 | QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES | SMITHKLINE BEECHAM PLC (GB) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999055677-A1 | QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES | SMITHKLINE BEECHAM PLC (GB) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | POLB 578/4885NR4A2 2675/4885ACHE 849/4885 |
| US-12091387-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | POLB 578/4885NR4A2 2675/4885ACHE 849/4885 |
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, SSB, NT5C2 | POLB 1445/4885NR4A2 616/4885ACHE 4260/4885 |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | POLB 578/4885NR4A2 2675/4885ACHE 849/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | POLB 578/4885NR4A2 2675/4885ACHE 849/4885 |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | POLB 578/4885NR4A2 2675/4885ACHE 849/4885 |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | POLB 1471/4885NR4A2 3585/4885ACHE 4085/4885 |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | POLB 578/4885NR4A2 2675/4885ACHE 849/4885 |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | POLB 2325/4885NR4A2 299/4885ACHE 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.